Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study
CDK4/6抑制剂治疗失败后HR阳性/HER2阴性转移性乳腺癌患者的二线治疗:来自HERMIONE-13研究的真实世界数据
期刊:
影响因子:
doi:10.1016/j.esmorw.2025.100665
Cazzaniga, M E; Cogliati, V; Rossi, E; Paris, I; Borella, F; Moretti, G; Garrone, O; Pistelli, M; Palumbo, R; Ferro, A; Vici, P; De Giorgi, U; Madaro, S; Coltelli, L; Giordano, M; Gambaro, A R; Nicoletti, S V L; Zustovich, F; Landucci, E; Gamucci, T; Pepe, F F; Galimberti, S; Capici, S